#Cancer21
New oral Listeria vaccine shows promise against colorectal cancer
Researchers report a modified oral vaccine made from Listeria that primes immune cells in the gut and limits tumor growth in mice. The vaccine worked best when combined with immune checkpoint inhibitors and caused few side effects.
Photo by Devi Puspita Amartha Yahya, Unsplash
Cherry compounds may slow triple-negative breast cancer
Researchers at Texas A&M report that anthocyanins from dark sweet cherries slowed tumour growth and reduced metastasis in mice, and that combining them with chemotherapy helped control tumours. Further research is needed on safety and absorption.
New modular CAR-T system controls where and when cells attack
Researchers at the University of Chicago created GA1CAR, a modular CAR-T system that uses short-lived Fab fragments to guide and pause tumor targeting. In animal tests the same cells were redirected to different tumors and remained functional.
Clock disruption speeds breast cancer in models
New research finds that repeating disruption of the body’s 24-hour clock changes breast tissue, weakens immune defenses and leads to faster, more aggressive breast cancer in experimental models. The study links altered light–dark schedules to worse outcomes.
Biosensor reveals cancer-specific vulnerability in PRMT5
Researchers found that a metabolite change in some tumors makes the protein PRMT5 bind MTA instead of SAM. A new NanoBRET biosensor and a probe called CBH-002 measure drug binding to this cancer-specific form of PRMT5 in live cells.
Lower chemotherapy dose helps people 80+ with lymphoma
A study found that people aged 80 and older with a common lymphoma often do better with a lower chemotherapy dose. Researchers used data from community cancer clinics and say the smaller dose kept effectiveness while reducing side effects.
Brown study suggests targeting mTORC2 could help fight cancer
Researchers at Brown University report that blocking the mTORC2 protein complex, while leaving mTORC1 active, may stop cancer growth signals without triggering survival pathways. The work offers a new direction for designing cancer drugs.